Ahamad Anesa, Stevens Craig W, Smythe W Roy, Vaporciyan Ara A, Komaki Ritsuko, Kelly Jason F, Liao Zhongxing, Starkschall George, Forster Kenneth M
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):768-75. doi: 10.1016/s0360-3016(02)04151-2.
Malignant pleural mesothelioma (MPM) causes symptoms and death mainly due to local progression, even after combined modality treatment. Poor local control after conventional radiotherapy may be due to the low dose of radiation that has been administered or to restriction of the target volume to avoid critical organs. Intensity-modulated radiation therapy (IMRT) has the potential to overcome these geometric/dosimetric constraints.
Seven patients with MPM who had an extrapleural pneumonectomy (EPP) were treated with adjuvant IMRT. The clinical target volume (CTV) included the surgically violated area inside the chest wall with particular attention to the insertion of the diaphragm, pleural reflections, and the deep margin of the thoracotomy incision. Treatment was delivered by intensity-modulated 6-MV photon beams using dynamic multileaf collimation.
The CTV ranged from 2667 to 7286 mL. The average CTV covered to 50 Gy was 94% (range, 92% to 98%). Respiratory motion was minimal. The average volume of the boost areas covered by 60 Gy was 92% (range, 82% to 99%). Dose-volume constraints for normal tissue were met in almost all cases. Acute toxicity was mild to moderate. The most severe side effects were anorexia, nausea or vomiting, and dyspnea. Esophagitis was absent or mild. After a minimum of 13 months follow-up care there were no cases of disease recurrence within the ipsilateral hemithorax.
Treatment of the extensive operative area after an EPP is feasible using IMRT. Input from the radiologist and from the surgeon in the planning process facilitates definition of the high dose volumes. In light of patients' tolerance to post-EPP IMRT, it may be feasible to incorporate systemic therapy, including novel biologic therapies into the treatment regimen.
恶性胸膜间皮瘤(MPM)主要因局部进展导致症状和死亡,即便接受综合治疗后亦是如此。传统放疗后局部控制不佳可能是由于所给予的辐射剂量较低,或者是为避免关键器官而限制了靶区体积。调强放射治疗(IMRT)有潜力克服这些几何/剂量学限制。
7例接受胸膜外全肺切除术(EPP)的MPM患者接受了辅助IMRT治疗。临床靶区(CTV)包括胸壁内手术侵犯区域,特别注意膈肌附着处、胸膜反折以及胸廓切开切口的深部边缘。使用动态多叶准直器,通过调强6兆伏光子束进行治疗。
CTV范围为2667至7286毫升。平均CTV接受50 Gy照射的覆盖率为94%(范围为92%至98%)。呼吸运动极小。接受60 Gy照射的加量区域平均体积为92%(范围为82%至99%)。几乎所有病例均满足正常组织的剂量体积限制。急性毒性为轻度至中度。最严重的副作用是厌食、恶心或呕吐以及呼吸困难。食管炎不存在或为轻度。经过至少13个月的随访,同侧半胸内无疾病复发病例。
使用IMRT治疗EPP后的广泛手术区域是可行的。在计划过程中放射科医生和外科医生的参与有助于确定高剂量区域。鉴于患者对EPP后IMRT的耐受性,将包括新型生物疗法在内的全身治疗纳入治疗方案可能是可行的。